Editas Medicine Inc. (Nasdaq: EDIT)

https://www.editasmedicine.com

LinkedIn: https://www.linkedin.com/company/editas-medicine

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. *

	Start	2013-11-25 established
	Industry	CRISPR gene editing technology
	Industry 2	TALEN® technology (Transcription Activator-Like Effector Nuclease)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	11 Hurley Street
	City	02141 Cambridge, MA
	Tel	+1-617-401-9000
		Address record changed: 2024-01-05

Basic data	Employees	D: 101 to 500 (2022-02-01)
	Currency	USD
	Annual sales	25,544,000 (revenues, consolidated (2021) 2021-12-31)
	Profit	-192,502,000 (2021-12-31)
	Cash	409,845,000 (2021-12-31)

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Editas Medicine Inc. (Nasdaq: EDIT)

[1] Editas Medicine, Inc.. (3/14/17). "Press Release: Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases". Dublin & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)